Hans Hammers
Verified account This account is verified. Learn more@HHammersMD
Medical oncologist with focus on kidney cancer, immunotherapies and the tumor microenvironment. Views expressed are my own. #kidneycancer #immunotherapy
689 Following 4.1K Followers 3.5K Posts
Latest posts 5
Absolutely no surprise here! 🎉👏 So well deserved @brian_rini & @tompowles1
A huge fan of @Uromigos and the brilliant Tom and Brian❤️ Their passion, wit, and ability to bring the global GU oncology community together for insightful, engaging, and entertaining conversations make this podcast truly special and unique with a 🌏 footprint!
Congratulations on this wonderful recognition! 🎙️🏆
@LosUromigos @uromigosjapan @OncoAlert @montypal @neerajaiims @Silke_Gillessen @PGrivasMDPhD @DrChoueiri @ChrisSweens1 @kalasri3
@myESMO @UroDocAshView quoted post on X
@CPRT65 Camillo Porta and @sophiemerrick1 for great PRO work and discussion of IO AEs and potential long term side effects.
The possibility of persistent worsening “neurocognitive function” must now be discussed with patients who are engaging with adjuvant IO. ESMO26
The possibility of persistent worsening “neurocognitive function” must now be discussed with patients who are engaging with adjuvant IO. ESMO26
This is a game changer!!
45% durable ORRs at higher dose levels.
READY for prime time and will change early treatment lines.
As excited as when I first saw PD1 results in RCC.
This will transform front lines and cure more patients.
45% durable ORRs at higher dose levels.
READY for prime time and will change early treatment lines.
As excited as when I first saw PD1 results in RCC.
This will transform front lines and cure more patients.
OncoAlert #Podium2Screen🚨 #ESMO26
XmAb819 in #RCC
Our @OncoAlert founding faculty @montypal 🇺🇸presents a first-in-class ENPP3 x CD3 bispecific in heavily pretreated ccRCC:
➡️ ORR 27%, DCR 68%
➡️ Activity after prior HIF-2α inhibitor (ORR 26%)
➡️ 15/16 responders still on treatment
#KidneyCancer
@AlbigesL, @MehmetAsimBilen
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3View quoted post on X
ENPP3 x CD3 ! Seismic Shift to come !!
Let’s end using non IO drugs in the frontline and focus on CURE!
Let’s end using non IO drugs in the frontline and focus on CURE!
Well well well…
This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape!
45% response in heavily pretreated pts. Highly impressive!
Needs to move into frontline combinations! Congrats @montypal + colleaguesView quoted post on X